294 related articles for article (PubMed ID: 27485642)
1. Development of a Flow-Through USP-4 Apparatus Drug Release Assay to Evaluate Doxorubicin Liposomes.
Yuan W; Kuai R; Dai Z; Yuan Y; Zheng N; Jiang W; Noble C; Hayes M; Szoka FC; Schwendeman A
AAPS J; 2017 Jan; 19(1):150-160. PubMed ID: 27485642
[TBL] [Abstract][Full Text] [Related]
2. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome.
Tang J; Srinivasan S; Yuan W; Ming R; Liu Y; Dai Z; Noble CO; Hayes ME; Zheng N; Jiang W; Szoka FC; Schwendeman A
Eur J Pharm Biopharm; 2019 Jan; 134():107-116. PubMed ID: 30481559
[TBL] [Abstract][Full Text] [Related]
3. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
4. Determination of key parameters for a mechanism-based model to predict Doxorubicin release from actively loaded liposomes.
Csuhai E; Kangarlou S; Xiang TX; Ponta A; Bummer P; Choi D; Anderson BD
J Pharm Sci; 2015 Mar; 104(3):1087-98. PubMed ID: 25561354
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug.
Maiti K; Bhowmick S; Jain P; Zope M; Doshi K; Rajamannar T
Anticancer Agents Med Chem; 2018; 18(4):597-609. PubMed ID: 29173186
[TBL] [Abstract][Full Text] [Related]
6. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic model and analysis of doxorubicin release from liposomal formulations.
Fugit KD; Xiang TX; Choi du H; Kangarlou S; Csuhai E; Bummer PM; Anderson BD
J Control Release; 2015 Nov; 217():82-91. PubMed ID: 26310713
[TBL] [Abstract][Full Text] [Related]
9. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
10. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
[TBL] [Abstract][Full Text] [Related]
11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
12. Simulation of Stimuli-Responsive and Stoichiometrically Controlled Release Rate of Doxorubicin from Liposomes in Tumor Interstitial Fluid.
Yamamoto E; Hyodo K; Suzuki T; Ishihara H; Kikuchi H; Kato M
Pharm Res; 2018 Mar; 35(5):103. PubMed ID: 29557075
[TBL] [Abstract][Full Text] [Related]
13. Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach.
Tefas LR; Sylvester B; Tomuta I; Sesarman A; Licarete E; Banciu M; Porfire A
Drug Des Devel Ther; 2017; 11():1605-1621. PubMed ID: 28579758
[TBL] [Abstract][Full Text] [Related]
14. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
15. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
16. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
Stevens PJ; Lee RJ
Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
18. Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS).
Ansar SM; Mudalige T
Int J Pharm; 2020 Jan; 574():118906. PubMed ID: 31805309
[TBL] [Abstract][Full Text] [Related]
19. A simple and rapid measurement method of encapsulation efficiency of doxorubicin loaded liposomes by direct injection of the liposomal suspension to liquid chromatography.
Yamamoto E; Miyazaki S; Aoyama C; Kato M
Int J Pharm; 2018 Jan; 536(1):21-28. PubMed ID: 29175642
[TBL] [Abstract][Full Text] [Related]
20. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]